METOCLOPRAMIDE Drug Patent Profile
✉ Email this page to a colleague
When do Metoclopramide patents expire, and when can generic versions of Metoclopramide launch?
Metoclopramide is a drug marketed by Avet Lifesciences, Bedford, Fresenius Kabi Usa, Hospira, Lyphomed, Norbrook, Smith And Nephew, Teva Pharms Usa, Actavis Mid Atlantic, Ani Pharms, Chartwell Molecular, Morton Grove, Paco, Pharm Assoc, Pharmobedient Cnsltg, Roxane, Teva, Vistapharm, Novel Labs Inc, Aiping Pharm Inc, Chartwell Rx, Clonmel, Halsey, Impax Labs Inc, Interpharm, Ipca Labs Ltd, Mutual Pharm, Northstar Hlthcare, Par Pharm, Sandoz, Schering, Strides Pharma, Sun Pharm Industries, Superpharm, Usl Pharma, and Watson Labs. and is included in fifty-five NDAs.
The generic ingredient in METOCLOPRAMIDE is metoclopramide hydrochloride. There are fourteen drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the metoclopramide hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Metoclopramide
A generic version of METOCLOPRAMIDE was approved as metoclopramide hydrochloride by TEVA on July 29th, 1985.
Summary for METOCLOPRAMIDE
US Patents: | 0 |
Applicants: | 36 |
NDAs: | 55 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 91 |
Clinical Trials: | 260 |
Patent Applications: | 4,309 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for METOCLOPRAMIDE |
Drug Sales Revenues: | Drug sales revenues for METOCLOPRAMIDE |
What excipients (inactive ingredients) are in METOCLOPRAMIDE? | METOCLOPRAMIDE excipients list |
DailyMed Link: | METOCLOPRAMIDE at DailyMed |
Recent Clinical Trials for METOCLOPRAMIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Genuine Research Center, Egypt | Phase 3 |
Adwia Pharma, Egypt | Phase 3 |
Sohag University | Phase 2/Phase 3 |
Pharmacology for METOCLOPRAMIDE
Drug Class | Dopamine-2 Receptor Antagonist |
Mechanism of Action | Dopamine D2 Antagonists |